The EMPEROR-Preserved trial compared the efficacy and safety of empagliflozin with placebo in adults with heart failure and preserved ejection fraction, with and without diabetes.
The new packaging allows for ease of administration and convenience.
SGLT2 inhibitors, compared with GLP-1 RAs, linked to lower risk for heart failure hospitalization in patients with T2DM, with or without CVD
Benefits for heart failure patients include functional capacity and fewer complications with newer devices
The designation is based on findings from the phase 3 EMPEROR-Preserved trial.
In FIDELITY, investigators pooled data from more than 13,000 patients from the FIDELIO-DKD and FIGARO-DKD trials.
The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes.
Doubled risk seen for high triglyceride, total/high-density lipoprotein, and apolipoprotein-A1
This week we have significant news on the status of a third COVID-19 vaccine booster dose, as well as news for an encephalitis vaccine, another Jardiance indication, an FDA warning concerning patient wristbands, and Jemperli gets accelerated approval.
The approval was based on data from the phase 3 EMPEROR-Reduced trial.
